LSE:DPH (Dechra Pharmaceuticals Plc)

About DPH

Dechra Pharmaceuticals PLC is a holding company, which engages in the veterinary pharmaceuticals and related products business. It operates through the following segments: European Pharmaceuticals; North American Pharmaceuticals; and Pharmaceuticals Research and Development. The European Pharmaceuticals segment markets and sells licensed pharmaceuticals and specialist pet foods to the veterinary profession in Europe. The North American Pharmaceuticals segment focuses on the sale of a range of endocrine, ophthalmic, dermatological, and equine products in North America. The Pharmaceuticals Research and Development segment develops and licenses Dechra's own branded veterinary product portfolio of novel and generic pharmaceuticals and specialist pet diets. The company was founded in 1819 and is headquartered in Northwich, the United Kingdom.
  • Dechra Pharmaceuticals Plc (LSE: DPH) Latest News

    Retirement Articles

    A top dividend growth stock I’d buy for my retirement fund in 2020

    Royston Wild reveals a top income buy for 2020 and beyond. Why not take a look?

    Read more »

    Retirement Articles

    Forget GlaxoSmithKline! 2 ‘better’ pharmaceutical stocks I think could help you retire in luxury

    Sure, GlaxoSmithKline plc (LON: GSK) has delivered some pretty decent shareholder returns over the past half a decade. But are…

    Read more »

    Investing Articles

    Expensive but exceptional! 3 FTSE 250 growth shares that could help you to retire early

    These FTSE 100 (INDEXFTSE: UKX) stocks may be expensive but they're worth every penny, argues Royston Wild.

    Read more »

    Investing Articles

    Want to get rich? 3 FTSE 250 growth stocks that I’d buy and hold for the next 10 years

    These growth giants from the FTSE 250 (INDEXFTSE: MCX) look set to thrive through the next 10 years at least,…

    Read more »

    Investing Articles

    I think these 2 fast-recovering FTSE 250 pharma growth stocks could make you richer

    Harvey Jones says these two FTSE 250 (INDEXFTSE: MCX) stocks are in fine form after a sickly year.

    Read more »

    Investing Articles

    2 FTSE 250 dividend stocks I’d buy and hold for 25 years

    Royston Wild zeroes in on two terrific FTSE 250 (INDEXFTSE: MCX) income heroes that could make you richer.

    Read more »

    Investing Articles

    GlaxoSmithKline isn’t the only pharmaceutical share I’d buy right now

    Why I’m tempted by GlaxoSmithKline plc (LON: GSK) and this fast-growing pharmaceutical firm.

    Read more »

    Investing Articles

    Top shares for September

    We asked our writers to share their top stock picks for the month.

    Read more »

    Investing Articles

    3 of the best growth stocks of 2018 (so far)

    Royston Wild runs the rule over three stocks whose share prices have detonated in 2018. Can they keep climbing?

    Read more »

    Investing Articles

    One super growth stock I’d buy ahead of SXX shares

    Edward Sheldon explains why he won't be buying shares of Sirius Minerals plc (LON: SXX).

    Read more »

    Investing Articles

    GlaxoSmithKline plc isn’t the only pharma stock I’d buy today

    Royston Wild explains why GlaxoSmithKline plc (LON: GSK) isn't the only pharma star that could make you a fortune.

    Read more »

    Investing Articles

    Does Halma plc’s double-digit growth make it the steal of the century?

    Halma plc (LON: HLMA) has seen its earnings soar, and here's another that's done even better.

    Read more »